CACatiele Antunes

Catiele Antunes

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Catiele Antunes has a total of 51 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Beyond CT-defined low muscle mass in cirrhosis: toward a more accessible diagnostic approach

    by Thiago Araújo de Melo, Catiele Antunes, Pedro Robson Costa Passos, Bruna Gomes Noronha, Alisson Barbosa Silva, Guilherme Grossi Lopes Cançado

  • Open Access

    Vonoprazan Improves Nocturnal Gastroesophageal Reflux Symptoms in Nonerosive Reflux Disease

    by Catiele Antunes, Gaurav Ghosh, Philip Katz, Rena Yadlapati, Eckhard Leifke, Tom Harris, Hillary Graham, Loren Laine

    INTRODUCTION: This analysis of a phase 3 randomized trial evaluated the efficacy of vonoprazan on prespecified end points for nighttime symptoms in patients with nonerosive reflux disease. METHODS: Adults with heartburn ≥4 d/wk and without erosive esophagitis were randomized to placebo, vonoprazan 10 mg, or vonoprazan 20 mg. After 4 weeks, subjects on placebo were rerandomized to vonoprazan 10 or 20 mg, and those already on vonoprazan continued the same dose for an additional 20 weeks. Nocturnal Gastro-esophageal Reflux Disease Symptom Severity and Impact Questionnaire (N-GSSIQ), a validated instrument for nocturnal gastroesophageal reflux disease, was completed at baseline and weeks 4, 12, and 24. Minimal important differences for N-GSSIQ total score and subscales were defined as ≥0.4. RESULTS: Among 772 subjects, the mean percentage of heartburn-free nights at week 4 was 43.3% for placebo vs 59.9% for vonoprazan 10 mg (least squares [LS] mean difference = 16.5%, P < 0.0001) and 56.4% for vonoprazan 20 mg (LS mean difference, 13.1%, P < 0.0001). Vonoprazan improved N-GSSIQ total score (LS mean difference vs placebo of −2.9 and −1.8 for vonoprazan 10 and 20 mg, respectively; P < 0.005 for both comparisons), nocturnal symptom severity subscale (LS mean difference vs placebo of −5.4 and −3.5 for vonoprazan 10 and 20 mg; P < 0.001 for both comparisons), and concern about nocturnal gastroesophageal reflux disease subscale (LS mean difference vs placebo of −2.0 for both vonoprazan 10 and 20 mg; P < 0.0001). The benefit on heartburn-free nights and N-GSSIQ scores was observed through the additional 20 weeks. DISCUSSION: Our study suggests that vonoprazan leads to relief of nighttime heartburn in patients with heartburn and a normal endoscopy.


  • Esophageal Radiography Interpretation: a Primer for the Gastroenterologist

    by Catiele Antunes, Joshua A. Sloan

    Purpose of Review Radiological studies can be helpful when evaluating patients with suspect esophageal disorders. From benign strictures to malignancy and motility disorders such as achalasia, imaging modalities play a significant role in diagnosis. This review explores the role of different imaging modalities in the most frequently encountered esophageal pathologies. Recent Findings Conventional barium esophagram has long been considered the primary imaging modality of the esophagus. In the same fashion, a timed barium esophagram is a valuable tool in the evaluation of achalasia and esophagogastric junction outlet obstruction. Over the last few decades there has been an increase in CT and MRI studies, which also play a role in the evaluation of esophageal pathologies. However, not infrequently, these newer imaging techniques can result in incidental esophageal findings. It is important that gastroenterologists appreciate the value of different modalities and recognize key imaging features. Summary The diagnosis and management of esophageal disorders is evolving. A basic understanding of esophageal radiology is essential to any gastroenterologist caring for patients with esophageal complaints.


  • Open Access

    Agrp Neurons Mediate Sirt1's Action on the Melanocortin System and Energy Balance: Roles for Sirt1 in Neuronal Firing and Synaptic Plasticity

    by Marcelo O. Dietrich, Catiele Antunes, Gan Geliang, Zhong-Wu Liu, Erzsebet Borok, Yongzhan Nie, Allison W. Xu, Diogo O. Souza, Qian Gao, Sabrina Diano, et al.

    Sirt1 has been associated with various effects of calorie restriction, including an increase in lifespan. Here we show in mice that a central regulatory component in energy metabolism, the hypothalamic melanocortin system, is affected by Sirt1, which promotes the activity and connectivity of this system resulting in negative energy balance. In adult mice, the pharmacological inhibition of brain Sirt1 activity decreased Agrp neuronal activity and the inhibitory tone on the anorexigenic POMC neurons, as measured by the number of synaptic inputs to these neurons. When a Sirt1 inhibitor (EX-527) was injected either peripherally (i.p., 10 mg/kg) or directly into the brain (i.c.v., 1.5 nmol/mouse), it decreased both food intake during the dark cycle and ghrelin-induced food intake. This effect on feeding is mediated by upstream melanocortin receptors, because the MC4R antagonist, SHU9119, reversed Sirt1's effect on food intake. This action of Sirt1 required an appropriate shift in the mitochondrial redox state: in the absence of such an adaptation enabled by the mitochondrial protein, UCP2, Sirt1-induced cellular and behavioral responses were impaired. In accordance with the pharmacological results, the selective knock-out of Sirt1 in hypothalamic Agrp neurons through the use of Cre-Lox technology decreased electric responses of Agrp neurons to ghrelin and decreased food intake, leading to decreased lean mass, fat mass, and body weight. The present data indicate that Sirt1 has a central mode of action by acting on the NPY/Agrp neurons to affect body metabolism.


  • Open Access

    Efeitos do cloreto de gadolínio na pancreatite induzida por tauracolato de sódio em ratos

    by Diego da Fonseca Mossmann, Maria Isabel Albano Edelweiss, Jane Maria Kulczynski, Norma Anair Possa Marroni, Nélson Alexandre Kretzmann, Catiele Antunes, Oscar Augusto Birkhan, Alessandro Bersch Osvaldt

    OBJETIVO: Avaliar os efeitos do uso de cloreto de gadolínio como pré-tratamento e tratamento em um modelo experimental de pancreatite em ratos induzida por tauracolato de sódio a 3%. MÉTODOS: Ratos Wistar foram divididos em cinco grupos: grupo SF - controle com solução fisiológica intra-ductal e IV; grupo TS - controle com PA induzida por tauracolato de sódio a 3% e solução fisiológica a 0,9% IV; grupo GD - controle com SF intra-ductal e cloreto de gadolínio IV; grupo GDTS - pré-tratamento com GD (24h antes da indução da PA) e grupo TSGD - tratamento com GD (1h após a indução da PA). Foi realizado dosagem sérica de amilase, transaminases e TNF-á; determinação da atividade da MPO no tecido pulmonar; histologia pancreática e pulmonar. RESULTADOS: O número de animais mortos antes do término previsto do experimento foi significativamente maior no grupo TSGD (p=0,046). Os escores de pancreatite e de dano pulmonar foram mais elevados nos grupos que utilizaram tauracolato em comparação aos grupos com infusão intra-ductal de solução salina. Não houve diferenças nas demais variáveis estudadas na comparação entre os grupos TS; GDTS e TSGD. CONCLUSÃO: Não foram demonstrados benefícios com o uso de cloreto de gadolínio de forma profilática e terapêutica.

  • Open Access

    Mechanisms involved in the antinociception induced by systemic administration of guanosine in mice

    by AP Schmidt, Ae Böhmer, C Schallenberger, C Antunes, Rg Tavares, St Wofchuk, E Elisabetsky, Do Souza

    Background and purpose: It is well known that adenine‐based purines exert multiple effects on pain transmission. However, less attention has been given to the potential effects of guanine‐based purines on pain transmission. The aim of this study was to investigate the effects of intraperitoneal (i.p.) and oral (p.o.) administration of guanosine on mice pain models. Additionally, investigation into the mechanisms of action of guanosine, its potential toxicity and cerebrospinal fluid (CSF) purine levels were also assessed.Experimental approach: Mice received an i.p. or p.o. administration of vehicle (0.1 mM NaOH) or guanosine (up to 240 mg·kg−1) and were evaluated in several pain models.Key results: Guanosine produced dose‐dependent antinociceptive effects in the hot‐plate, glutamate, capsaicin, formalin and acetic acid models, but it was ineffective in the tail‐flick test. Additionally, guanosine produced a significant inhibition of biting behaviour induced by i.t. injection of glutamate, AMPA, kainate and trans‐ACPD, but not against NMDA, substance P or capsaicin. The antinociceptive effects of guanosine were prevented by selective and non‐selective adenosine receptor antagonists. Systemic administration of guanosine (120 mg·kg−1) induced an approximately sevenfold increase on CSF guanosine levels. Guanosine prevented the increase on spinal cord glutamate uptake induced by intraplantar capsaicin.Conclusions and implications: This study provides new evidence on the mechanism of action of the antinociceptive effects after systemic administration of guanosine. These effects seem to be related to the modulation of adenosine A1and A2Areceptors and non‐NMDA glutamate receptors.


  • Electrophysiological effects of guanosine and MK-801 in a quinolinic acid-induced seizure model

    by Felipe V. Torres, Manoel da Silva Filho, Catiele Antunes, Eduardo Kalinine, Eduardo Antoniolli, Luis V.C. Portela, Diogo O. Souza, Adriano B.L. Tort


  • Spinal mechanisms of antinociceptive action caused by guanosine in mice

    by André P. Schmidt, Ana Elisa Böhmer, Cristhine Schallenberger, Catiele Antunes, Mery Stéfani L. Pereira, Renata Leke, Susana T. Wofchuk, Elaine Elisabetsky, Diogo O. Souza


  • Open Access

    Anti‐nociceptive properties of the xanthine oxidase inhibitor allopurinol in mice: role of A1adenosine receptors

    by AP Schmidt, Ae Böhmer, C Antunes, C Schallenberger, Lo Porciúncula, E Elisabetsky, D R Lara, Do Souza

    Background and purpose: Allopurinol is a potent inhibitor of the enzyme xanthine oxidase, used primarily in the treatment of hyperuricemia and gout. It is well known that purines exert multiple effects on pain transmission. We hypothesized that the inhibition of xanthine oxidase by allopurinol, thereby reducing purine degradation, could be a valid strategy to enhance purinergic activity. The aim of this study was to investigate the anti‐nociceptive profile of allopurinol on chemical and thermal pain models in mice.Experimental approach: Mice received an intraperitoneal (i.p.) injection of vehicle (Tween 10%) or allopurinol (10–400 mg kg−1). Anti‐nociceptive effects were measured with intraplantar capsaicin, intraplantar glutamate, tail‐flick or hot‐plate tests.Key results: Allopurinol presented dose‐dependent anti‐nociceptive effects in all models. The opioid antagonist naloxone did not affect these anti‐nociceptive effects. The non‐selective adenosine‐receptor antagonist caffeine and the selective A1adenosine‐receptor antagonist, DPCPX, but not the selective A2Aadenosine‐receptor antagonist, SCH58261, completely prevented allopurinol‐induced anti‐nociception. No obvious motor deficits were produced by allopurinol, at doses up to 200 mg kg−1. Allopurinol also caused an increase in cerebrospinal fluid levels of purines, including the nucleosides adenosine and guanosine, and decreased cerebrospinal fluid concentration of uric acid.Conclusions and implications: Allopurinol‐induced anti‐nociception may be related to adenosine accumulation. Allopurinol is an old and extensively used compound and seems to be well tolerated with no obvious central nervous system toxic effects at high doses. This drug may be useful to treat pain syndromes in humans.


  • Antinociceptive effects of intracerebroventricular administration of guanine-based purines in mice: Evidences for the mechanism of action

    by André P. Schmidt, Ana Elisa Böhmer, Renata Leke, Cristhine Schallenberger, Catiele Antunes, Mery Stéfani L. Pereira, Susana T. Wofchuk, Elaine Elisabetsky, Diogo O. Souza